Journal of the American College of Cardiology
Volume 58, Issue 13, 20 September 2011, Pages 1325-1331
Clinical ResearchInterventional CardiologyBiodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease: 3-Year Outcomes From a Randomized Clinical Trial
Interventional Cardiology
Under an Elsevier user license
open archive
Key Words
biodegradable
drug-eluting stent
everolimus
polymer
randomized trial
restenosis
sirolimus
Abbreviations and Acronyms
CI
confidence interval
DES
drug-eluting stent(s)
EES
everolimus-eluting stent(s)
HR
hazard ratio
MI
myocardial infarction
SES
sirolimus-eluting stent(s)
TLR
target lesion revascularization
Cited by (0)
The microporous metal stent backbone used in the biodegradable polymer drug-eluting stent is produced by Translumina, Hechingen, Germany, who had no input into the study design, conduct, or funding. Drs. Kastrati and Schömig hold a patent related to the biodegradable polymer coating. Dr. Kastrati has received lecture fees from Abbott, Biotronik, Biosensors, Cordis, and Medtronic. Dr. Mehilli has received lecture fees from Abbott and Cordis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.